Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TAF-I alpha (F3E2E) Rabbit Monoclonal Antibody #97411

Filter:
  • WB
  • IP

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 45
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:10 - 1:50
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TAF-I alpha (F3E2E) Rabbit Monoclonal Antibody recognizes endogenous levels of total TAF-Iα protein. This antibody does not cross-react with TAF-Iβ protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro8 of human TAF-Iα protein.

    Background

    Templated activating factor I (TAF-I), also known as SET, is a histone chaperone protein first discovered to play a role in adenovirus chromatin replication (1,2). TAF-I is an acidic protein capable of binding histone cores and remodeling nucleosomes (3). TAF-I is part of the inhibitor of acetyltransferases (INHAT) complex, which sharply represses histone acetylation by PCAF and P300/CBP (4). INHAT complex binding to histone tails is affected by certain histone marks (5). TAF-I has two predominant isoforms, TAF-Iα and TAF-Iβ, which only differ in the N-terminus. TAF-Iα is the predominant isoform in embryonic stem cells, and its expression is regulated by pluripotent factors. Upon differentiation, an isoform shift takes place as the alternative promoter is upregulated, generating TAF-Iβ (6-8). TAF-I uniquely exhibits histone chaperone activity toward linker histone H1, regulating higher-order chromatin structure. TAF-Iα has less activity than TAF-Iβ due to its inhibitory interaction between its unique N-terminus and the C-terminus (9,10). TAF-I has been implicated in oncogenic transformation by inhibiting apoptosis (11).

    Alternate Names

    2PP2A; chromatin remodelling factor; HLA-DR-associated protein II; I-2PP2A; I2PP2A; IGAAD; Inhibitor of granzyme A-activated DNase; inhibitor-2 of protein phosphatase-2A; IPP2A2; MRD58; PHAPII; Phosphatase 2A inhibitor I2PP2A; protein phosphatase type 2A inhibitor; Protein SET; SET; SET nuclear oncogene; SET nuclear proto-oncogene; SET translocation (myeloid leukemia-associated); TAF-I; TAF-IBETA; Template-activating factor I; Template-Activating Factor-I, chromatin remodelling factor

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.